2,400+ researchers supplied
99+ COAs published
6-panel tested every lot
Processing within 1–3 business days
FREE SHIPFree U.S. shipping on orders over $150Free U.S. shipping on orders over $150
Free U.S. shipping on orders over $150TB500 peptide is a shorter, bioactive fragment of thymosin beta-4, designed to focus on thymosin beta-4’s most therapeutically relevant region, the 7-amino acid sequence LKKTETQ responsible for actin binding and tissue regeneration [1]. Though structurally simpler than the full-length thymosin beta-4, TB500 peptide retains potent biological activity [5]. The number 500 in TB500 is added as a commercial name, without biological or scientific significance.
Key biochemical features include:
TB500 exerts multi-system effects, supporting wound healing, reducing inflammation, promoting cell regeneration, and enhancing immune defenses [1].
TB500 accelerates tissue repair by binding actin, a key structural protein in cells. This interaction stimulates stem cell recruitment and differentiation at injury sites, migration of skin cells to close wounds faster, and formation of new blood vessels (angiogenesis) to improve oxygen and nutrient delivery [1].
It also enhances collagen alignment and increases laminin-5, both essential for strong and well-structured tissues [7]. Simultaneously, it reduces the number of scar-forming cells, minimizing fibrotic tissue formation [8].
Animal studies have confirmed TB500 peptide’s ability to reduce tissue damage, speed up recovery, and promote healing even in challenging conditions [9]. Human trials suggest that topical formulations are safe and effective in wound repair. Emerging data also support the potential role of TB500 in neurological and cardiac tissue regeneration, aiding recovery after events like stroke or heart attack [9].
Following tissue injury, high levels of inflammation can damage tissues and lead to permanent scarring. TB500 peptide mitigates this response, lowering the levels of inflammatory cells and the chemical signals they release [1]. This has downstream impacts of reducing tissue swelling, protecting healthy tissue, and creating an environment supportive of proper healing with less scar tissue formation [1].
A key anti-inflammatory mechanism involves the NF-kB signalling pathway, which controls the expression of many pro-inflammatory genes. TB500 inhibits NF-kB activation, prevents p65 subunit phosphorylation, and blocks nuclear translocation of NF-kB [10]. These actions have been demonstrated in corneal, cardiac, and liver tissues. The NF-kB inhibition contributes to reduced inflammation and improved healing responses in these tissues [10].
TB500 peptide modulates the toll-like receptor-4 (TLR-4) pathway, which is central to innate immune responses [11]. Through upregulation of microRNA-146a, TB500 can suppress this pathway, promoting anti-inflammatory effects [11]. For this reason, TB500 may indirectly support the repair of gut barriers by improving the proliferation and migration of cells, and supporting tissue healing processes.
Furthermore, a peptide fragment within TB500, Ac-SDKP, has been shown to reduce fibrosis (e.g., heart scarring after myocardial infarction), likely through similar anti-inflammatory and anti-proliferative mechanisms [6].
TB500 strengthens antimicrobial defenses by increasing the expression of antimicrobial peptides (AMPs) such as keratin 6A, CAMP, beta-defensins (BD2, BD3), and S100A8 [12]. These peptides help prevent bacterial adherence and enhance immune clearance of pathogens [12].
TB500 also boosts TLR4 expression, enhancing the recognition of bacterial invaders like LPS-producing pathogens [12]. When combined with antibiotics, TB500 enhances the activity of 12-LOX and 15-LOX enzymes, which promote resolution of inflammation and tissue restoration [12].
This synergy highlights TB500’s potential as an adjunct to antimicrobial therapies—supporting not only microbial defense but also repair of infected tissues.
Research Use Only. All findings described above are derived from preclinical studies (animal models and in vitro experiments). Thymosin Beta-4 is not approved by the FDA for any diagnostic or therapeutic use in humans. Genesis Peptides makes no claims regarding human clinical efficacy. This product is sold exclusively for laboratory research.
Every lot undergoes six independent assays before release. Results are published in the lot-specific Certificate of Analysis.
One review names TB-500 as a thymosin beta-4 fragment and lists it among unapproved peptides marketed direct to patients. A separate scoping review states that thymosin beta-4, also called TB-500, is one of six emerging peptides it summarizes for musculoskeletal recovery and enhancement in animal and human models.
According to the review, thymosin beta 4 (TB4) has not received full US Food and Drug Administration approval. The review reports that studies show TB4 significantly promotes corneal wound healing after injury, and that this led to a clinical trial of RGN-259, with full FDA approval still pending. The review also states that most of these regenerative peptides, which include TB-4, remain unapproved by the FDA, and that clinical evidence in humans is limited.
In a randomized, placebo-controlled, double-blind trial of 96 STEMI patients, the overall difference in infarcted area between the rhTB4 group and the placebo group was not significant. In a subgroup of that trial, infarcted areas were significantly reduced at 90-day follow-up in patients whose first rhTB4 dose was given within 8 h after PCI (n = 43) compared with placebo.
In structural modeling, the tandem form (tTB4) was found to be able to simultaneously bind and sequester two G-actin molecules, which gave it a mechanistic advantage over standard TB4 in enhancing actin polymerization. In a murine alkali-induced corneal injury model, tTB4 promoted corneal wound healing and reduced scarring with greater efficacy than TB4. Because tTB4 can be produced by bacterial fermentation, its synthesis is described as simplified and more cost-effective than that of TB4.
In a mouse model of Pseudomonas aeruginosa keratitis, adjunctive thymosin beta 4 (Tβ4) combined with ciprofloxacin markedly improved visual acuity and contrast sensitivity compared with PBS, Tβ4 alone, and ciprofloxacin alone. In the infected mice, the combination of Tβ4 and ciprofloxacin also restored corneal nerve density and architecture to levels comparable to those of uninfected control mice. In this animal study, the treatments were given as topical drops three times daily, starting 24 hours after infection.
In rat studies, TB-500 treatment was associated with increased type I collagen organization and altered type III collagen distribution on Sirius red birefringence analysis, particularly in the TB-500 group. Histopathological evaluation in rats showed significantly lower total Bonar scores in the TB-500 group (p = 0.016), and significantly lower total Movin scores in the TB-500 and BPC + TB groups relative to controls, indicating improved tendon architecture. In rats, biomechanical testing found higher maximum load to failure values in the BPC-157 and TB-500 groups than in controls, with the difference reaching statistical significance in the TB-500 group (p < 0.05).
In a cell-based (in vitro) study, thymosin beta 4 was identified as a neuroprotective factor that may mitigate altered neurogenesis and Alzheimer's disease pathology. In an animal study, thymosin beta 4 had beneficial effects in 5xfAD model mice.
In animal studies, thymosin beta 4 (Tβ4) was investigated for enhancing fat graft survival by facilitating mitochondrial transfer from adipose-derived stem cells to adipocytes and newly formed blood vessels within the grafts via tunneling nanotubes. In these animal studies, the Tβ4-driven mitochondrial transfer was reported to mitigate oxidative stress, reduce apoptosis, and promote revascularization, thereby improving the quality and volume retention of fat grafts.
A review reports that current limitations of thymosin beta 4 (TB4)-based therapies are a short half-life and high peptide synthesis costs. The review notes that these limitations restrict large-scale applications of such therapies.
In a human clinical study of patients with type 2 diabetes, plasma proteomic analysis found that thymosin beta 4 was among the circulating proteins whose abundance differed between patients with and without diabetic foot syndrome. In the same human clinical study, thymosin beta 4 was described as differing between diabetic foot syndrome patients and diabetic controls, and it was explored in relation to systemic inflammatory variables. These findings describe a difference in abundance between the groups, as reported in patients.
In the animal study, co-treatment with mesenchymal stem cells (MSCs) and thymosin beta-4 (Tβ4) yielded the best therapeutic outcome against dry eye, surpassing the outcomes of either monotherapy. Using matrix-assisted laser desorption/ionization mass spectrometry imaging, the researchers found increased glutamine levels in the cornea after combined MSC + Tβ4 therapy.
FOR RESEARCH USE ONLY — Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.